A New Multisystem Disorder Caused by the Gαs Mutation p.F376V.
Alleles
Amino Acid Substitution
Bone and Bones
/ abnormalities
Chromogranins
/ genetics
DNA Mutational Analysis
Female
GTP-Binding Protein alpha Subunits, Gs
/ genetics
Gain of Function Mutation
Heterozygote
Humans
Hyponatremia
/ genetics
Loss of Function Mutation
Male
Maternal Inheritance
Phenotype
Pseudohypoparathyroidism
Puberty, Precocious
/ genetics
Journal
The Journal of clinical endocrinology and metabolism
ISSN: 1945-7197
Titre abrégé: J Clin Endocrinol Metab
Pays: United States
ID NLM: 0375362
Informations de publication
Date de publication:
01 04 2019
01 04 2019
Historique:
received:
08
06
2018
accepted:
08
10
2018
pubmed:
13
10
2018
medline:
15
2
2020
entrez:
13
10
2018
Statut:
ppublish
Résumé
The α subunit of the stimulatory G protein (Gαs) links numerous receptors to adenylyl cyclase. Gαs, encoded by GNAS, is expressed predominantly from the maternal allele in certain tissues. Thus, maternal heterozygous loss-of-function mutations cause hormonal resistance, as in pseudohypoparathyroidism type Ia, whereas somatic gain-of-function mutations cause hormone-independent endocrine stimulation, as in McCune-Albright syndrome. We report two unrelated boys presenting with a new combination of clinical findings that suggest both gain and loss of Gαs function. Clinical features were studied and sequencing of GNAS was performed. Signaling capacities of wild-type and mutant Gαs were determined in the presence of different G protein-coupled receptors (GPCRs) under basal and agonist-stimulated conditions. Both unrelated patients presented with unexplained hyponatremia in infancy, followed by severe early onset gonadotrophin-independent precocious puberty and skeletal abnormalities. An identical heterozygous de novo variant (c.1136T>G; p.F376V) was found on the maternal GNAS allele in both patients; this resulted in a clinical phenotype that differed from known Gαs-related diseases and suggested gain of function at the vasopressin 2 receptor (V2R) and lutropin/choriogonadotropin receptor (LHCGR), yet increased serum PTH concentrations indicative of impaired proximal tubular PTH1 receptor (PTH1R) function. In vitro studies demonstrated that Gαs-F376V enhanced ligand-independent signaling at the PTH1R, LHCGR, and V2R and, at the same time, blunted ligand-dependent responses. Structural homology modeling suggested mutation-induced modifications at the C-terminal α5 helix of Gαs that are relevant for interaction with GPCRs and signal transduction. The Gαs p.F376V mutation causes a previously unrecognized multisystem disorder.
Identifiants
pubmed: 30312418
pii: 5126388
doi: 10.1210/jc.2018-01250
pmc: PMC6380466
doi:
Substances chimiques
Chromogranins
0
GNAS protein, human
EC 3.6.1.-
GTP-Binding Protein alpha Subunits, Gs
EC 3.6.5.1
Types de publication
Case Reports
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1079-1089Subventions
Organisme : Department of Health
Pays : United Kingdom
Organisme : NIDDK NIH HHS
ID : R01 DK046718
Pays : United States
Organisme : NIDDK NIH HHS
ID : P01 DK011794
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK113039
Pays : United States
Organisme : NIDDK NIH HHS
ID : R56 DK046718
Pays : United States
Organisme : NIDDK NIH HHS
ID : R37 DK046718
Pays : United States
Organisme : NIAMS NIH HHS
ID : P30 AR066261
Pays : United States
Informations de copyright
Copyright © 2019 Endocrine Society.
Références
Nat Struct Mol Biol. 2006 Sep;13(9):772-7
pubmed: 16892066
Annu Rev Med. 2004;55:27-39
pubmed: 14746508
J Biol Chem. 2003 Dec 5;278(49):48666-73
pubmed: 14504270
Trends Pharmacol Sci. 2018 May;39(5):481-493
pubmed: 29548548
Nature. 2011 Jul 19;477(7366):549-55
pubmed: 21772288
N Engl J Med. 1999 Apr 1;340(13):1012-20
pubmed: 10099144
Hum Mutat. 2000 Sep;16(3):183-9
pubmed: 10980525
Trends Pharmacol Sci. 2006 May;27(5):260-6
pubmed: 16600389
N Engl J Med. 1991 Dec 12;325(24):1688-95
pubmed: 1944469
Science. 1997 Dec 12;278(5345):1943-7
pubmed: 9395396
Nature. 2018 Jun;558(7711):559-563
pubmed: 29925945
Science. 2015 Jun 19;348(6241):1361-5
pubmed: 26089515
Nature. 2018 Jun;558(7711):547-552
pubmed: 29899455
N Engl J Med. 2013 Jun 27;368(26):2476-2486
pubmed: 23802516
Mol Endocrinol. 2002 Aug;16(8):1912-9
pubmed: 12145344
J Mol Biol. 2009 Nov 6;393(4):882-97
pubmed: 19703466
Gene. 2011 Apr 15;475(2):63-78
pubmed: 21182906
J Bone Miner Res. 2017 Apr;32(4):776-783
pubmed: 28084650
Cell. 1995 Dec 15;83(6):1047-58
pubmed: 8521505
Cell. 2018 May 17;173(5):1254-1264.e11
pubmed: 29628140
Nature. 1994 Sep 8;371(6493):164-8
pubmed: 8072545
J Clin Endocrinol Metab. 2010 Aug;95(8):3605-10
pubmed: 20501679
Nat Rev Cancer. 2013 Jun;13(6):412-24
pubmed: 23640210
J Bone Miner Res. 1999 Jun;14(6):1016
pubmed: 10352113
Mol Interv. 2004 Dec;4(6):326-36
pubmed: 15616162
Nature. 2011 Sep 28;477(7366):611-5
pubmed: 21956331
Nature. 1993 Oct 14;365(6447):652-4
pubmed: 7692306
Nature. 2018 Jun;558(7711):620-623
pubmed: 29925951
J Clin Endocrinol Metab. 2012 Sep;97(9):E1782-90
pubmed: 22745241
Nat Struct Mol Biol. 2014 Jan;21(1):56-63
pubmed: 24292645
J Bone Miner Res. 1999 Nov;14(11):1987-9
pubmed: 10571700
J Biol Chem. 2014 Aug 29;289(35):24475-87
pubmed: 25037222
Nature. 2008 Sep 25;455(7212):497-502
pubmed: 18818650
Proc Natl Acad Sci U S A. 2009 Jun 30;106(26):10660-5
pubmed: 19541654
Am J Kidney Dis. 2012 Apr;59(4):566-8
pubmed: 22154540